<--- Back to Details
First PageDocument Content
Cancer treatments / Adjuvant therapy / Dysplastic nevus syndrome / Sentinel lymph node / Dacarbazine / DecisionDx-UM / Medicine / Oncology / Melanoma
Date: 2012-05-01 11:12:36
Cancer treatments
Adjuvant therapy
Dysplastic nevus syndrome
Sentinel lymph node
Dacarbazine
DecisionDx-UM
Medicine
Oncology
Melanoma

ASCO Classic Oncology References Melanoma Epidemiology/Biology 1. Barnhill RL, Katzen J, Spatz A, et al The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol; 2005 Apr; 32

Add to Reading List

Source URL: university.asco.org

Download Document from Source Website

File Size: 227,85 KB

Share Document on Facebook

Similar Documents

Microsoft WordDabrafenib GSK PSD March 13 final...docx

Microsoft WordDabrafenib GSK PSD March 13 final...docx

DocID: 12uHM - View Document

Microsoft WordVemurafenib Roche  PSD MArch 2013 FINAL.doc

Microsoft WordVemurafenib Roche PSD MArch 2013 FINAL.doc

DocID: 12mhw - View Document

Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens

Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens

DocID: ZKrT - View Document

Kill or Cure Chemotherapy Answers: 1. Combination chemotherapy regime: Adriamycin (or doxorubicin), Vinblastine, Bleomycin, Dacarbazine. 2. Directly compared with the pre-therapy scan: previous disease in the right axill

Kill or Cure Chemotherapy Answers: 1. Combination chemotherapy regime: Adriamycin (or doxorubicin), Vinblastine, Bleomycin, Dacarbazine. 2. Directly compared with the pre-therapy scan: previous disease in the right axill

DocID: Yz0i - View Document

dabrafenib, 50mg and 75mg hard capsules (TafinlarĀ®) GlaxoSmithKline SMC No. (No[removed]February 2015

dabrafenib, 50mg and 75mg hard capsules (TafinlarĀ®) GlaxoSmithKline SMC No. (No[removed]February 2015

DocID: WZc4 - View Document